Second-quarter fiscal 2009 results announced by AmexDrug

Sep 8 2009

AmexDrug Corporation (OTCBB: AXRX), a vertically integrated pharmaceutical and cosmeceutical company, today announced second quarter 2009 financial results.

"Our second quarter and months earlier this year showcase the most significant developments since the company's inception," said Jack Amin, President and CEO of AmexDrug Corp.

Second Quarter 2009 Highlights:

-- Revenues increased 65.7% year-over-year to a record of $2.43 million.

-- Gross profit increased $256,928, compared to the second quarter of 2008, representing a gross margin increase of 209.3%.

-- Costs of Goods Sold increased 57.1% year-over-year to a record of $2.17 million.

-- Expenses increased 22.0% year-to-year to a record of $115,493.

-- Net income was up to $79,159, a significant increase from the prior year largely attributed to the increase in sales.

"AmexDrug Corporation is expanding. Our profits are increasing. And our cultivated company culture is attracting the best talent in the country," said Amin. "With our latest expansion into Asia Pacific, our affiliated network offices are fine-tuned and expected to increase revenues moving into 2010."